Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Durvalumab and Lurbinectedin in Relapsed Extensive Stage Small Cell Lung Cancer
NCT04607954Phase 2Active, not recruiting
- Sponsor
- Mayo Clinic
- Start
- Dec 2020
- Primary completion
- Mar 2026
- Modality
- Antibody Conjugates, DNA Intercalators/Alkylators, Classical Binding Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of durvalumab, lurbinectedin in small cell lung cancer (SCLC), sponsored by Mayo Clinic. Started Dec 2020; status: active, not recruiting.
02
Drugs
durvalumablurbinectedin
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT04607954.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04607954.